Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a report published on Thursday.

Several other brokerages have also commented on ALNY. Scotiabank lowered their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research report on Friday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright lifted their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $310.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Stock Up 0.0 %

Alnylam Pharmaceuticals stock opened at $241.76 on Thursday. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market cap of $31.30 billion, a PE ratio of -111.41 and a beta of 0.39. The firm’s 50-day simple moving average is $255.17 and its 200 day simple moving average is $260.11. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Research analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. Regeneron Pharmaceuticals Inc. purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $1,045,822,000. Norges Bank purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $577,941,000. Capital Research Global Investors grew its stake in Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock worth $1,031,705,000 after buying an additional 1,245,195 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company’s stock worth $89,100,000 after buying an additional 315,182 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.